What's Happening?
The U.S. Food and Drug Administration (FDA) has approved Galderma's Differin Epiduo Acne Gel for over-the-counter (OTC) use, marking a significant transition from prescription-only to OTC availability.
This approval allows individuals aged 12 and older to access a dermatologist-recommended, prescription-strength acne treatment without needing a prescription. The gel combines adapalene, a third-generation retinoid, with benzoyl peroxide, an antimicrobial agent, to target multiple causes of acne. This combination has been shown to clear clogged pores, kill acne-causing bacteria, and reduce inflammation. The approval is backed by over 15 years of real-world use and extensive clinical research, demonstrating the product's efficacy and safety. The gel will be available at major retailers such as Walmart, Ulta, Target, and Amazon starting in the summer of 2026.
Why It's Important?
This FDA approval is significant as it expands access to effective acne treatment for millions of Americans, particularly teenagers and young adults who are most affected by acne. By transitioning from prescription-only to OTC, Galderma is making a proven treatment more accessible, potentially reducing the need for dermatologist visits and associated healthcare costs. The move also underscores Galderma's leadership in dermatology and its commitment to advancing acne care through innovation. For consumers, the availability of a potent, scientifically-backed treatment without a prescription simplifies the process of managing acne, potentially improving adherence to treatment regimens and outcomes.
What's Next?
With the OTC launch of Differin Epiduo, Galderma is poised to strengthen its position in the acne treatment market. The company plans to continue its commitment to providing comprehensive acne care solutions, including cleansers, treatments, and moisturizers. As the product becomes available, consumer response and market uptake will be closely monitored. Dermatologists and healthcare providers may also adjust their recommendations based on the availability of this OTC option. Additionally, Galderma's success with this transition could encourage other pharmaceutical companies to consider similar prescription-to-OTC switches for their products.
